Nine Square is developing novel treatments for neurodegenerative and age-related diseases by correcting autophagy dysfunction. Our programs are directed to high value, genetically validated targets and leverage target engagement and pathway activation biomarkers to accelerate clinical development. We expect to file an IND for our TRPML1 program in Q1 2026, with a fast-to-market strategy for Multiple System Atrophy and potential to expand into Dementia with Lewy Bodies and Parkinson's Disease. We plan to file an IND for our Parkin program in Q2 2026, with a focus on Parkinson's Disease.